Pulmonology experts update their knowledge on the latest treatments in COPD, as well as in the management of the ecobronscopia.

-These days have enabled specialists improve their management in the implementation of ecobroncoscopia, a new tool for diagnosing cancer bronchopulmonary, very safe and with a high diagnostic yield

Seville, January 2013- the disease chronic obstructive pulmonary (COPD) affects nearly two million people in Spainbeing the main consequence of smoking in our country and of their environment. Dyspnea and exercise intolerance are some of its most crippling symptoms, which are closely related to bronchial obstruction and air entrapment, which in turn translates into medium and long term, even with a high degree of mortality and a decrease in cardiac pumping ability. Bronchodilators are the most effective drugs to treat this disease as they get to control successfully the clinical symptoms, improve lung function, reduce exacerbations and improve the quality of life of patients suffering from COPD.

Dr. Francisco Casas, President of NEUMOSUR and director of the first regional Conference of COPD, during the inauguration of the.

So this past weekend during the celebration of the first Conference of COPD in Seville, and organised by the Association of Pulmonology and surgery thoracic South (NEUMOSUR), whose specialists presented the latest concerning in the treatment of this respiratory pathology explained. In this sense, be advanced that the development of new bronchodilators of long duration (LABA, adrenergic, and LAMA, anticolergenicos, according to its acronym in English) allow a relevant improvement in the treatment of this disease, which contributes to a better outcome for the patient and a decrease in health care costs. In certain patients, that improvement may be higher if combine these drugs among themselves or with inhaled corticosteroids.

The Conference on COPD held in Seville, coordinated by Dr. Francisco Casas, President of NEUMOSUR, have also served specialists in the treatment of respiratory diseases to improve their skills in the accomplishment of ecobroncoscopias, new tool for the diagnosis of bronchopulmonary, very safe cancer and with a high diagnostic yield. Specialists gathered in Seville, however, indicate that this profitability can be enhanced through the implementation of protocols that allow process and study samples obtained quickly.